Hoth Therapeutics is rebranding as Rocket One and pivoting toward space-focused AI chip infrastructure, targeting low-power, radiation-tolerant computing systems for orbital and defense applications.
Key Investor Takeaways
- Hoth Therapeutics (NASDAQ:HOTH) will begin trading as Rocket One Inc. under the ticker symbol (NASDAQ:RKTO) on May 28, 2026.
- The company is repositioning around nanomagnetic AI chip technology designed for space and defense computing environments.
- Rocket One said it holds exclusive rights to low-power, radiation-tolerant AI chip and memory technologies.
- Management is targeting growth opportunities tied to satellites, orbital AI systems, nanosatellites, and defense infrastructure.
- The company’s biotechnology programs will continue operating under a wholly owned subsidiary.
Why RKTO Stock Is in Focus
Hoth Therapeutics announced it has officially changed its corporate name to Rocket One Inc. and will begin trading under the Nasdaq ticker symbol RKTO beginning May 28, 2026.
The rebrand follows the company’s previously disclosed strategic repositioning toward the orbital economy and space-based computing infrastructure.
According to Rocket One, the company is focusing on next-generation nanomagnetic AI chip technology designed for energy-constrained and radiation-heavy environments such as:
- low-Earth orbit
- deep-space platforms
- satellites
- defense systems
The company said the technology differs from traditional silicon-based chips by using nanoscale magnetism to perform AI-related computations.
Rocket One highlighted several intended advantages of the technology, including:
- retention of data without continuous power
- reduced energy consumption
- smaller hardware footprint
- edge AI processing capabilities for satellites and defense applications
Management said the company intends to pursue three primary strategic areas:
- AI chip and memory hardware for orbital and radiation-heavy environments
- Nano-launch and nanosatellite systems
- Defense and national security applications
The company also stated that its biotechnology programs, including HT-001, HT-KIT, HT-ALZ, and its GDNF-related metabolic platform, will continue under a wholly owned subsidiary structure.
“Space is moving from a launch story to a compute story,” said Chief Executive Officer Robb Knie.
“We believe that the platforms that will define the next decade in orbit will be the ones that can think for themselves under power and radiation constraints that ground-based hardware was never designed to handle.”
Knie added: “Our exclusive licenses give us a credible technical foundation, and the RKTO ticker is a signal to investors, partners, and customers that our focus is now on the orbital economy.”
Why This Matters for Investors
The announcement represents a major strategic transformation for the company, shifting investor focus away from biotechnology and toward space infrastructure and AI hardware markets.
The move positions Rocket One within several high-profile investment themes simultaneously, including:
- space economy infrastructure
- AI hardware
- defense technology
- edge computing
- satellite systems
The company appears to be targeting a specific challenge facing modern satellite and orbital systems: running AI workloads efficiently under strict energy and radiation constraints.
For investors, the repositioning could potentially broaden Rocket One’s addressable market if the company successfully commercializes its nanomagnetic computing technology.
However, the transition also introduces substantial execution risk. The company is entering highly competitive and technically demanding industries dominated by established semiconductor, aerospace, and defense players.
The release also does not include:
- commercialization timelines
- production milestones
- customer agreements
- revenue projections
- prototype validation data
As a result, investor sentiment may remain tied largely to future technical progress and partnership development rather than near-term financial performance.
The continuation of the biotech pipeline under a subsidiary structure may also leave investors evaluating how management allocates resources across two very different operating segments.
What to Watch Next
Investors may monitor:
- Technical validation milestones for the nanomagnetic AI chip platform
- Potential aerospace or defense partnerships
- Progress in nanosatellite and orbital computing initiatives
- Commercialization strategy for AI hardware
- Government or national security contract opportunities
- Future disclosures around prototypes, testing, or manufacturing
- The operational structure separating biotech and space-focused businesses